Cathie Wood’s ARK Invest recently made some changes to its portfolio, buying CRISPR stock while selling off holdings in L3Harris and Vertex. The move comes as part of ARK’s strategy to capitalize on emerging trends and technologies in the market. CRISPR, a gene-editing technology, has been gaining attention for its potential to revolutionize healthcare and agriculture. Meanwhile, L3Harris and Vertex were sold off, possibly to reallocate funds towards more promising investments. ARK’s investment decisions are closely watched by many investors, as the firm has a track record of spotting successful trends early on.